SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory ...
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and ...
Alpine Immune Sciences Inc (NASDAQ:ALPN) presents promising clinical data for povetacicept at ASN Kidney Week. Successful $150 million equity offering to fuel development activities into 2026.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...
Good afternoon, ladies and gentlemen, and thank you for joining the Alpine Immune Sciences fourth-quarter 2020 financial results and corporate update conference call. [Operator instructions] As a ...
Alpine Immune Sciences, Inc. ALPN announced that it has entered into a collaboration and supply agreement with pharma giant Merck MRK for conducting an immuno-oncology study. The study – NEON-2 – ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Alpine Immune Sciences, Inc. ALPN announced that it has entered into a collaboration and supply agreement with pharma giant Merck MRK for conducting an immuno-oncology study. The study – NEON-2 – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results